Karyopharm Therapeutics Inc
KPTI5.410USD
-0.320-5.58%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
46.78MCap. mercado
PérdidaP/E TTM
Más Datos de Karyopharm Therapeutics Inc Compañía
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Información de la empresa
Símbolo de cotizaciónKPTI
Nombre de la empresaKaryopharm Therapeutics Inc
Fecha de salida a bolsaNov 06, 2013
Director ejecutivoMr. Richard A. Paulson
Número de empleados279
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 06
Dirección85 Wells Avenue
CiudadNEWTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02459
Teléfono16176580600
Sitio Webhttps://karyopharm.com/
Símbolo de cotizaciónKPTI
Fecha de salida a bolsaNov 06, 2013
Director ejecutivoMr. Richard A. Paulson
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Otro
72.51%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Otro
72.51%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
20.86%
Hedge Fund
16.35%
Research Firm
7.96%
Corporation
5.28%
Investment Advisor/Hedge Fund
4.11%
Venture Capital
1.83%
Individual Investor
1.14%
Bank and Trust
0.03%
Otro
42.45%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
BofA Global Research (US)
132.91K
1.54%
+122.13K
+1132.80%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Fecha
Tipo
Relación
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
